Luma Vision has announced the successful first-in-human device use and enrolment in its LUMINIZE clinical study involving the “groundbreaking” Verafeye platform. A company press release states that this cutting-edge, four-dimensional catheter-based imaging system is designed to “transform” the field of interventional electrophysiology by providing “unprecedented” real-time visualisation of the heart’s chambers. The system magnetically tracks the navigation of third-party catheters, empowering clinicians to perform complex procedures with greater precision and control.
Verafeye combines state-of-the-art imaging technology with advanced manoeuvrability, enabling clinicians to capture highly detailed, four-dimensional images that update in real time. According to Luma, this allows for dynamic, high-resolution navigation and visualisation of the heart—something that the company says is “crucial” to performing today’s advanced electrophysiology procedures with a wide variety of technologies.
Traditional imaging catheters provide only two-dimensional imaging, often limiting clinicians’ ability to view cardiac anatomy from all angles during procedures. However, as Luma notes, the Verafeye catheter introduces a new era of intracardiac imaging, allowing for comprehensive, 360-degree visualisation with enhanced depth and clarity. This enables the Verafeye Rapid Digital Anatomy (RDA) feature, which allows clinicians to build computed tomography (CT)-quality reconstructions of both atrial chambers in under 60 seconds.
The first procedures—performed at the Mater Private Network (Dublin, Ireland) under the guidance of leading electrophysiologist Gabor Széplaki—demonstrated the Verafeye system’s potential to improve procedural workflows by enhancing accuracy, visualisation, and control.
“The Verafeye system provides a level of detail and real-time spatial context that is unmatched by traditional imaging methods,” said Széplaki. “This innovative technology represents a major leap forward in our ability to deliver precise and effective treatments for patients with complex heart conditions. Verafeye has the ability to provide all the navigation and imaging needed during today’s single-shot procedures in one system.”
“We are thrilled by this milestone and the future possibilities it opens for cardiac care in areas such as cardiac arrhythmias, left atrial appendage closure and structural heart conditions,” added Fionn Lahart, chief executive officer (CEO) at Luma. “The development of Verafeye is a testament to our team’s commitment to pushing the boundaries of medical technology and, with imminent market approval, we can equip clinicians with the tools they need to achieve better outcomes for patients worldwide.”
